Showing 7021-7030 of 8649 results for "".
- Bausch + Lomb Publishes Phase 4 Data on the Early Effects of Miebo for Dry Eye Diseasehttps://modernod.com/news/bausch-lomb-publishes-phase-4-data-on-the-early-effects-of-miebo-for-dry-eye-disease/2482715/Bausch + Lomb announced that Ophthalmology and Therapy has published results from a phase 4 study which assessed early patient-reported outcomes with Miebo in patients wit
- Study Finds Most Glaucoma Patients Unaware of Preservative-Free Treatment Optionshttps://modernod.com/news/60-of-glaucoma-patients-unaware-of-preservative-free-treatment-options-study-from-preservative-freedom-coalition/2482698/The Preservative Freedom Coalition announced the results of a new nationwide survey delving into the experience of glaucoma patients to identify opportunities for improved communication with their eye care providers. This comes as Monday kicked o
- BVI Medical Raises $1 Billion to Fuel Global Growthhttps://modernod.com/news/bvi-medical-raises-1-billion-to-fuel-global-growth/2482692/BVI Medical has completed a $1 billion strategic capital raise in partnership with asset management firm TPG. According to BVI, the investment, which fully refinances BVI’s existing debt and adds new equity from both TPG and new investors, aims to strengthen the company&
- Lumata Health Secures $23 Million Series B Fundinghttps://modernod.com/news/lumata-health-secures-23-million-series-b-funding/2482691/Lumata Health announced that it has raised $23 million in Series B funding, bringing its total raised since inception to $36 million. Lumata said the investment will enable the company to meet growing demand and further enhance the data-driven technology powering its patient adherence s
- Opus Genetics Doses First Pediatric Patient in Phase 1/2 Trial for OPGx-LCA5 Gene Therapyhttps://modernod.com/news/opus-genetics-doses-first-pediatric-patient-in-phase-12-trial-for-opgx-lca5-gene-therapy/2482675/Opus Genetics announced the first pediatric patient has been dosed in its ongoing phase 1/2 clinical trial evaluating OPGx-LCA5, its investigational gene therapy for Leber congenital amaurosis (LCA). Initial data from the pediatric cohort is expected to be shared by Q3
- MyEyeDr. Partners with CoFi to Streamline Patient Paymentshttps://modernod.com/news/myeyedr-partners-with-cofi-to-streamline-patient-payments/2482673/MyEyeDr., which has 880 locations across the US, has teamed up with multi-party payment provider CoFi to simplify the payment process for patients requiring both optometry and ophthalmology services. This new partnership, now available in all 29 states where MyEyeDr. o
- FDA Clears New World Medical's VIA360 Surgical Systemhttps://modernod.com/news/fda-clears-new-world-medicals-via360-surgical-system/2482667/New World Medical has received 510(k) clearance from the FDA for its VIA360 Surgical System for the delivery of controlled amounts of viscoelastic fluid during ophthalmic surgeries. The VIA360, which is also indicated to cut trabecular meshwork tissue during trabecul
- Fred Moll, Founder of Intuitive Surgical, Joins ForSight Robotics Board of Directorshttps://modernod.com/news/fred-moll-founder-of-intuitive-surgical-joins-forsight-robotics-board-of-directors/2482664/ForSight Robotics announced that Fred Moll, MD, the founder of Intuitive Surgical, has joined its Board of Directors. Intuitive Surgical is the company behind the da Vinci surgical system, the first robotic surgical platform commercially available in the US 
- Bausch + Lomb: No Immediate Plans to Go Privatehttps://modernod.com/news/bausch-lomb-no-immediate-plans-to-go-private/2482653/After exploring options to separate from Bausch Health, Bausch + Lomb announced Thursday it decided not to engage in a sale. “Taking Bausch + Lomb private with a third-party buyer was one of several options being explored to complete a full separation from Bausch Health Companies
- Pykus Therapeutics to Present Initial Clinical Data on Novel Retinal Sealanthttps://modernod.com/news/pykus-therapeutics-to-present-initial-clinical-data-on-novel-retinal-sealant/2482651/Pykus Therapeutics announced that it will present initial clinical data on its investigational retinal sealant, PYK-2101, to replace gas and oil during retinal detachment repair. The data will be presented at the Vail Vitrectomy 2025 Meeting on February 10, 2025. The presentat